The National Health Regulatory Authority (NHRA) announced the licensing of "Foundayo" (orfoglipron), an oral GLP-1 medication used for obesity treatment.
The licensing allows "Foundayo" to enter the Bahraini market through pharmacies, provided it is used according to approved medical guidelines and following the necessary medical consultation, ensuring its safe use based on the patient’s health condition.
The approval of the medication represents an important step in expanding obesity treatment options and addressing related health challenges, in line with global developments in the treatment of obesity and associated chronic diseases.
The licensing comes as part of NHRA’s efforts to further develop the regulatory framework for pharmaceutical products and keep pace with medical and therapeutic development, enhancing the quality of healthcare services and supporting the continued development of Bahrain’s health sector by providing patients with modern treatments in accordance with the highest approved regulatory and medical standards.
&uuid=(email))